Table 1 Demographic and clinical characteristics of the study population
Characteristics | Total(N = 102) | Non-cirrhosis(N = 59) | cirrhosis(N = 43) | p |
|---|---|---|---|---|
Age (Year) | 28.5 (10.5) | 26.5 (10.1) | 31.2 (10.6) | 0.024 |
Male/female(N) | 62/40 | 33/26 | 29/14 | 0.332 |
Spleen | ||||
Normal/ splenomegaly (N) | 44 /58 | 26 /33 | 18/25 | 0.984 |
Ascites | ||||
-/+(N) | 91/11 | 58/1 | 33/10 | <0.001 |
AST (U/L) | 24.0 (20.0, 31.8) | 23.0 (18.5, 29.5) | 28.0 (22.0, 35.0) | 0.034 |
ALT (U/L) | 22.5 (17.0, 36.0) | 21.0 (16.0, 41.5) | 24.0 (17.0, 35.0) | 0.551 |
PLT (x109/L) | 148 (106, 201) | 166 (123, 200) | 115 (52.5, 218) | 0.007 |
ALB (g/l) | 39.8 (36.8, 42.2) | 40.8 (38.3, 43.0) | 37.5 (32.3, 40.2) | <0.001 |
PT (sec) | 11.4(10.7, 12.5) | 11.1(10.4, 11.7) | 11.9(11.2, 14.0) | < 0.001 |
Serum copper (umol/L) | 4.00 (2.13, 5.97) | 4.00 (2.08, 5.85) | 4.06 (2.50, 6.65) | 0.456 |
CP (g/L) | 0.09 (0.06, 0.10) | 0.09 (0.06, 0.10) | 0.09 (0.05, 0.10) | 0.904 |
Copper oxidase (/L) | 0.02 (0.02, 0.04) | 0.02 (0.02, 0.03) | 0.02 (0.02, 0.05) | 0.082 |
24 h urine copper (ug/24 h) | 785 (499, 1263) | 772 (480, 1262) | 809 (611, 1288) | 0.560 |
Serum zinc (umol/L) | 20.6 (13.3, 72.9) | 20.9 (13.5, 81.3) | 18.0 (12.5, 60.0) | 0.403 |
24 h urine zinc(ug/24 h) | 3132 (1947, 5059) | 3175(1936,4500) | 2996(2062,5796) | 0.792 |
LN (ng/ml) | 86.0 (53.0, 104) | 84.0 (59.3, 102) | 90.0 (53.0, 104) | 0.714 |
HA (ng/ml) | 78.1 (53.0, 116) | 78.2 (51.8, 135) | 76.7 (53.0, 96.6) | 0.412 |
CIV (ng/ml) | 48.2 (31.9, 57.6) | 51.7 (31.9, 68.7) | 41.8 (21.8, 57.0) | 0.089 |
P III N-P (ng/ml) | 10.6 (8.01, 14.0) | 10.4 (7.89, 13.9) | 10.6 (8.56, 14.2) | 0.402 |
PVV (cm/s) | 17.1 (15.3, 19.1) | 17.5 (16.3, 19.9) | 16.0 (14.3, 18.5) | 0.009 |
PVD (mm) | 12.0 (10.0, 13.0) | 11.0 (9.00, 12.0) | 13.0 (11.5, 15.0) | <0.001 |
ARFI (m/s) | 1.85 (0.35) | 1.67 (0.24) | 2.09 (0.33) | <0.001 |